Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ACACB | O00763 | 6/20 | 0.53 |
| ▸ | ACACA | Q13085 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL255663 | 1.00 | CYP1A2 (0.71) | CYP1A2SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL255664 | 1.00 | CYP1A2 (0.71) | CYP1A2SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL5473681 | 0.86 | SMN1; SMN2 (0.64) | CYP1A2SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL3985690 | 0.84 | SMN1; SMN2 (0.67) | CYP1A2SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL619526 | 0.84 | SMN1; SMN2 (0.67) | CYP1A2SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL2007222 | 0.84 | SMN1; SMN2 (0.67) | CYP1A2SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL13778592 | 0.83 | ACACB (0.56) | ACACBACACA | |
| SCHEMBL3721881 | 0.83 | CYP1A2 (0.54) | CYP1A2SMN1; SMN2POLBACACBACACA | |
| SCHEMBL8309864 | 0.82 | SMN1; SMN2 (0.60) | CYP1A2SMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL14521538 | 0.82 | SMN1; SMN2 (0.60) | CYP1A2SMN1; SMN2POLBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| CN-116249556-A | Antibody conjugation chemical inducer for degrading BRM and method thereof | 基因泰克公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-4185328-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | Genentech, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| WO-2022020288-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| EP-3194367-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3194367-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3865494-A1 | METAL COMPLEX, INTERMEDIATE, AND PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2021-08-18 | — | — | EP | disclosed |
| CN-106061480-B | Therapeutic inhibitory compounds | 莱福斯希医药公司 | 2020-02-28 | — | — | CN | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| WO-2012028676-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012001107-A1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012001107-A1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011080211-A1 | PESTICIDAL ARYLPYRROLIDINES | BAYER CROPSCIENCE AG (DE) | 2011-07-07 | — | — | WO | disclosed |
| WO-2010084090-A1 | PYRIDYL-AZA(THIO)XANTHONE SENSITIZER COMPRISING LANTHANIDE(III) ION COMPLEXING COMPOUNDS, THEIR LUMINESCENT LANTHANIDE (III) ION COMPLEXES AND USE THEREOF AS FLUORESCENT LABELS. | CIS BIO INTERNATIONAL (FR) | 2010-07-29 | — | — | WO | disclosed |
| US-7642256-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| US-7642256-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| US-20090118280-A1 | Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine | HARRISON STEPHEN | 2009-05-07 | — | — | US | disclosed |
| US-20090118280-A1 | Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine | HARRISON STEPHEN | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | P2RX5, P2RX3, ABCG2 | CYP1A2 133/4885SMN1; SMN2 4388/4885POLB 2247/4885 |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | ADRM1, CD79B, BRDT | CYP1A2 3562/4885SMN1; SMN2 1994/4885POLB 2560/4885 |
| US-20090118280-A1 | Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine | GRIN1, GRM2, GRM1 | CYP1A2 2601/4885SMN1; SMN2 3074/4885POLB 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.